Poltreg S.A. (WSE:PTG)

Poland flag Poland · Delayed Price · Currency is PLN
16.85
-0.15 (-0.88%)
Apr 8, 2026, 2:27 PM CET
Market Cap79.28M -51.4%
Revenue (ttm)n/a -75.0%
Net Income-24.56M
EPS-5.27
Shares Out4.66M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,215
Average Volume14,385
Open17.00
Previous Close17.00
Day's Range16.85 - 17.25
52-Week Range16.00 - 38.70
Beta0.98
RSI27.34
Earnings DateApr 15, 2026

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdańsk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 33
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.

Financial Statements